Iovance Biotherapeutics Inc
SWB:2LB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Iovance Biotherapeutics Inc
SWB:2LB
|
US |
|
Diebold Nixdorf Inc
F:DBDB
|
US |
|
Pepkor Holdings Ltd
F:S1VA
|
ZA |
|
SITC International Holdings Co Ltd
F:7S8
|
HK |
|
F
|
FibroGen Inc
BMV:FGEN
|
US |
|
S
|
Societe BIC SA
XMUN:BIF
|
FR |
|
Evercore Inc
NYSE:EVR
|
US |
|
Forvia SE
OTC:FAURY
|
FR |
|
K
|
Koninklijke Philips NV
XMUN:PHI1
|
NL |
|
P
|
Parker-Hannifin Corp
SWB:PAR
|
US |
|
H
|
Healthcare Trust Of America Inc
F:HT01
|
US |
|
O
|
Osaka Gas Co Ltd
F:OSA
|
JP |
|
SK Inc
KRX:034730
|
KR |
Wall St Price Targets
2LB Price Targets Summary
Iovance Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for 2LB is 7.649 EUR with a low forecast of 3.496 EUR and a high forecast of 12.719 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 2LB's stock price target?
Price Target
7.649
EUR
According to Wall Street analysts, the average 1-year price target for 2LB is 7.649 EUR with a low forecast of 3.496 EUR and a high forecast of 12.719 EUR.
What is the Revenue forecast for Iovance Biotherapeutics Inc?
Projected CAGR
29%
The compound annual growth rate for Revenue over the next 8 years is 29%.
What is the Gross Profit forecast for Iovance Biotherapeutics Inc?
Projected CAGR
43%
The compound annual growth rate for Gross Profit over the next 8 years is 43%.
